Recent Updates
Recently added Catalysts
GCTK Positive Sentiment Score: 75/100

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

Wednesday, July 29, 2026 1 min read
Key Takeaway: Lōkahi Therapeutics has announced advancements in its LT-100 development strategy, aiming to reduce the administration method from 15 intradermal injections to a single subcutaneous injection. This change is expected to enhance patient compliance and convenience. The company discussed this strategy during a Type C meeting with the FDA in May 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Simplification of treatment from 15 injections to 1 injection.
  • Potential for improved patient compliance and convenience.
  • Positive engagement with the FDA during Type C meeting.

Full Press Release Details

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company d

Frequently Asked Questions

What is the LT-100 development strategy?

The LT-100 strategy aims to simplify treatment from multiple injections to a single subcutaneous injection.

How many injections were previously required for LT-100?

Previously, up to 15 intradermal injections were required per treatment visit.

What did Lōkahi discuss with the FDA?

Lōkahi discussed their new single injection strategy during a Type C meeting with the FDA.

What are the benefits of the new injection method?

The new method is expected to improve patient compliance and convenience.

Tags: GCTK Viatris Investor Conferences Healthcare Lōkahi Therapeutics LT-100 FDA single injection
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$4M liquidity · $1M/mo burn
~0 mo
High dilution risk